In particular, TRF1 chemical inhibitors have been demonstrated to recapitulate the TRF1 knockdown phenotype and reduce tumor growth in xenografts from patient‐derived primary Glioma Stem Cells (GSCs) (Bejarano et al, 2019). The gene discussed is TERF1; the disease is glioma.